Earnings Call Summary | Theriva Biologics(TOVX.US) Q4 2023 Earnings Conference
Earnings Call Summary | Theriva Biologics(TOVX.US) Q4 2023 Earnings Conference
The following is a summary of the Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript:
以下是Theriva Biologics, Inc.（TOVX）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Theriva Biologics reported a decrease in general and administrative expenses from $9.9 million to $7.1 million, a decrease of 28% for 2023.
Research and development expenses increased from $11.7 million for 2022 to $14.3 million for 2023, which is primarily due to higher clinical trial expenses related to the VIRAGE Phase 2 trial of VCN-01 in PDAC.
As of December 31, 2023, Theriva Biologics had $23.2 million in cash and cash equivalents, compared to $41.8 million as of December 31, 2022.
Theriva Biologics報告稱，一般和管理費用從990萬美元減少到710萬美元，2023年下降了28％。
研發費用從2022年的1170萬美元增加到2023年的1,430萬美元，這主要是由於與PDAC中VIRAGE VCN-01 2期試驗相關的臨床試驗費用增加。
截至2023年12月31日，Theriva Biologics擁有2320萬美元的現金及現金等價物，而截至2022年12月31日爲4180萬美元。
Business Progress:
業務進展：
Theriva Biologics continues to build its oncology-focused portfolio, focusing on opportunities for its lead clinical candidate, VCN-01.
The VIRAGE Phase 2b trial of VCN-01 showed positive safety and feasibility results with improved clinical outcomes, and it aims to complete enrolment in the first half of 2024.
Completed patient treatments for the Phase 1 trial on retinoblastoma are expected to have follow-ups finalized by the first half of 2024.
With plans to increase R&D expenses due to the enrolment and expansion of clinical trials, the company expects to sustain its cash runway into Q1, 2025.
After enrolling patients in the second cohort for the Phase 1b/2a trial of SYN-004, expectations are for enrolment to complete in Q2, 2024.
Multiple discussions are ongoing regarding potential partnerships for the VCN-01 platform, SYN-004 and SYN-020 programs.
The focus remains on driving program advancement, effective cash management, and strategic options to drive additional shareholder value while delivering promising treatments for difficult to treat cancers.
Theriva Biologics繼續建立以腫瘤學爲重點的產品組合，重點關注其主要臨床候選藥物 VCN-01 的機會。
VCN-01 的 VIRAGE 2b 期試驗顯示出積極的安全性和可行性結果，臨床結果有所改善，其目標是在 2024 年上半年完成入組。
視網膜母細胞瘤1期試驗已完成的患者治療預計將在2024年上半年完成隨訪。
由於臨床試驗的註冊和擴大，該公司計劃增加研發費用，該公司預計其現金流將持續到2025年第一季度。
在將患者納入第二組患者參加 SYN-004 1b/2a 期試驗後，預計入組工作將於 2024 年第二季度完成。
關於 VCN-01 平台、SYN-004 和 SYN-020 計劃的潛在合作伙伴關係的多項討論正在進行中。
重點仍然是推動項目進展、有效的現金管理和戰略選擇，以增加股東價值，同時爲難以治療的癌症提供有前途的治療方法。
More details: Theriva Biologics IR
更多詳情： Theriva Biologics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。